Insights
Insights From Our Experts
Articles
Brave New Commercialisation World
The pharma commercialization landscape is evolving at an unprecedented speed. At Frontiers Health 2025, our team joined industry leaders to discuss how global launches, pricing strategies and patient access are being reshaped by policy changes and…
Google Cloud Spotlights EVERSANA: A Milestone for Pharma Innovation
When one of the world’s leading technology companies tells your story, it’s more than recognition. It’s validation of a vision that’s reshaping an entire industry. Google Cloud recently published a feature on EVERSANA’s approach to transforming…
EVDAS 2026: From Regulatory Requirement to Signal Advantage
The European Medicines Agency (EMA) has adopted Implementing Regulation (EU) 2025/1466, amending Regulation 520/2012 and reinforcing the requirement for ongoing monitoring of EudraVigilance data. From 12 February 2026, Marketing Authorisation Holders (MAHs) in the EU/EEA must…
Human-in-the-Loop + AI: A Pragmatic Path Forward for Pharma Commercialization
In a recent industry webinar, senior leaders from across the life sciences spectrum gathered to discuss the evolving role of artificial intelligence in commercialization. While the promise of AI is undeniable, the consensus was clear: In…
Balancing Privacy, Compliance and Personalization in Direct-to-Patient Models
In healthcare today, the direct-to-patient (DTP) model is reshaping how patients manage and control their treatment, information and support. DTP is a reorientation of existing commercialization capabilities across the patient journey, in a way that reduces…
Content Acceleration Like Never Before: Meet Our AI Agency Platform
In today’s life sciences landscape, speed and precision are no longer nice-to-haves—they’re necessities for keeping pace with the needs of patients and providers and ahead of the competition. That’s why we launched the industry’s first end-to-end,…
AI in Oncology: Acceleration, Accessibility, and Accuracy
At ESMO 2025, the conversation around artificial intelligence in oncology was impossible to ignore. From accelerating drug development to enabling remote patient monitoring, AI is completely changing cancer care— and EVERSANA has consistently leveraged these innovations…
AI at ESMO 2025: Navigating the New Frontier of Opportunity and Obstacles in Oncology
For the first time in its history, the European Society for Medical Oncology (ESMO) dedicated an entire track to Artificial Intelligence (AI) at its 2025 conference. For those who partner with pharmaceutical and biotech companies to…
Content Evolution: Shifting to Component-Based Authoring and Modular Strategies
Posted by
Mary Mehrabian, PharmD, BCGP, BCMAS , Michael DeLuca, PharmD, MBA, MSRA , Varun Pandey, PhD , Natalia Gandarillas, MPharm on October 28, 202510/28/25
The pharmaceutical industry is experiencing a major transformation in how Medical Affairs teams create and share content with healthcare professionals and patients. Gone are the days of static, one-size-fits-all materials. Today, organizations are embracing component-based authoring…
Interpretation of the Europe Regulatory Framework and Best Practices for MI Across the Pharma Industry
Posted by
Michael DeLuca, PharmD, MBA, MSRA , Varun Pandey, PhD , Lindsey Buyskes, B Pharm , Natalia Gandarillas, MPharm on October 28, 202510/28/25
Navigating the European regulatory landscape for Medical Information (MI) is no easy feat. Recent research reveals that MI teams across pharma companies—large and small—face a patchwork of requirements and best practices, from consent handling and call…